7.4.2. intravesical chemotherapy. 7.4.2.1. single, immediate, post-operative intravesical instillation chemotherapy immediate single instillation (si) shown act destroying circulating tumour cells turb, ablative effect residual tumour cells resection site small overlooked tumours [264-267]. four large meta-analyses comprising 1,476 3,103 patients consistently shown turb, si significantly reduces recurrence rate compared turb alone [268-271]. systematic review individual patient data meta-analysis 2,278 eligible patients , si reduced 5-year recurrence rate 14%, 59% 45%. patients primary tumours intermediate-risk recurrent tumours prior recurrence rate < 1 recurrence/year 2006 eortc recurrence score < 5 benefited si. patients 2006 eortc recurrence score > 5 and/or patients prior recurrence rate > 1 recurrence per year, si effective single adjuvant treatment. randomised comparisons individual drugs conducted [268-271]. single instillation mitomycin c (mmc), epirubicin pirarubicin , well gemcitabine , shown lower intravesical recurrence rate. single instillation gemcitabine superior saline rct approximately 200 patients per arm remarkably low toxicity rates . findings contrast previous study, which, however, used shorter instillation time . böhle et al., study, continuous saline irrigation used 24 hours post-operatively arms, could explain low recurrence rate control arm . prevention tumour cell implantation initiated within first hours turb. that, tumour cells firmly implanted covered extracellular matrix [264,274-276]. si studies, instillation administered within 24 hours. two rcts found overall impact si apaziquone, bio reductive prodrug similar mmc; contrast, post-hoc analysis find reduction recurrence risk patients receiving apaziquone within 90 minutes following turb . maximise efficacy si, one devise flexible practices allow instillation given soon possible turb, preferably within first two hours recovery room even operating theatre. severe complications reported patients drug extravasation, safety measures maintained (see section 7.7) . allow optimal compliance level 1 evidence, clinical teams encouraged explore barriers facilitators within practice . 7.4.2.2. additional adjuvant intravesical chemotherapy instillations need adjuvant intravesical therapy depends prognosis. low-risk patients (tables 6.1 6.2), si reduces risk recurrence considered standard complete treatment . patients, however, si remains incomplete treatment considerable likelihood recurrence and/or progression (tables 6.1 6.2). efficacy data following comparisons application schemes published. single installation vs. si repeat instillationsin one study, chemotherapy instillations si improved rfs intermediate-risk patients . repeat chemotherapy instillations vs. adjuvant treatmenta large meta-analysis 3,703 patients 11 rcts showed highly significant (44%) reduction odds recurrence one year favour chemotherapy turb alone . corresponds absolute difference 13–14% proportion patients recurrence. contrary findings, two meta- analyses demonstrated bcg therapy may also reduce risk tumour progression (see section 7.2.2.1). moreover, bcg maintenance therapy appears significantly better preventing recurrences chemotherapy [285-287] (see section 7.2.2.1). however, bcg causes significantly side effects chemotherapy . single instillation + repeat instillations vs. later repeat instillations onlythere evidence several studies intermediate-risk patients si might impact recurrence even adjuvant instillations given [288-291]. rct including 2,243 nmibc patients, compared si mmc instillation mmc delayed two weeks turb (followed repeat instillations treatment arms), showed significant reduction 9% risk recurrence 3 years favour si, 36% 27%. effect significant intermediate- high-risk groups patients receiving additional adjuvant mmc instillations . since author’s definition risk groups differed significantly initial publication, adapted patient stratification second analysis consistently showed improved efficacy si followed repeat mmc instillations . results study considered caution since patients receive adequate therapy. another rct found impact si epirubicin followed chemotherapy bcg instillations cohort predominant hr bc patients . optimal schedule intravesical chemotherapy instillationsthe length frequency repeat chemotherapy instillations still controversial; however, exceed one year . systematic review 16 comparative studies concluded available evidence support use maintenance chemotherapy induction treatment nmibc . 7.4.2.3. measures improve efficacy intravesical chemotherapy 7.4.2.3.1. adjustment ph, duration instillation, drug concentration two prospective rcts showed optimized intravesical administration mmc reduced recurrence rates, either combination measures (higher mmc-dose, peroral sodium bicarbonate, refraining drinking) adding cytosine arabinoside , respectively. value measures addition alternative maintenance schedules known however mmc admixtures ≥ 1 mg/ml achieve full solubilisation might lead decreased drug exposure bladder . another trial reported duration one- hour instillation mmc effective compared 30-minute instillation, efficacy comparisons available one- vs. two-hour durations instillation . another rct using epirubicin documented concentration important treatment duration . view data, instructions provided (see section 7.7). 7.4.2.3.2. device-assisted intravesical chemotherapy hyperthermic intravesical chemotherapydifferent technologies increase temperature instilled mmc available. recent systematic review meta-analysis including four rcts suggests similar toxicity bcg maintenance schedule . microwave-induced hyperthermia effect (rite)promising data presented enhancing efficacy mmc using microwave-induced hyperthermia patients high-risk tumours . one rct comparing one year bcg one year mmc microwave-induced hyperthermia patients intermediate- high-risk bc, increased rfs 24 months mmc group demonstrated . conductive chemohyperthermiain open-label phase ii rct including 259 patients, hivec chemo-hyperthermia failed demonstrate improvement dfs 24 months standard adjuvant intravesical chemotherapy intermediate-risk nmibc (61% vs. 60%), higher risk treatment discontinuation (59% vs. 89% completed planned treatments) . results line multicentre hivec 1 phase 3 open label rct, including 212 intermediate-risk patients, showing four-month adjuvant hyperthermic mmc using combat system intermediate-risk nmibc well tolerated, superior normothermic mmc 24 months . pilot phase ii rct 50 high-risk nmibcs, hivec™ mmc showed early outcomes comparable bcg (24 months rfs, 86.5% hivec™ 71.8% bcg, p = 0.184) . data need corroborated studies. electromotive drug administrationthe efficacy mmc using electromotive drug administration (emda) sequentially combined bcg patients high-risk tumours demonstrated one small rct . definitive conclusion, however, needs confirmation. application device-assisted instillations patients recurring bcg treatment, see section 7.9.3. 7.4.2.4. summary evidence - intravesical chemotherapy summary evidencelein patients low-risk nmibc small ta lg/g1 recurrence detected one year previous turb, si significantly reduces recurrence rate compared turb alone.1asingle instillation might impact recurrence even adjuvant chemotherapy instillations given, high-risk nmibc treated adjuvant bcg.3repeat chemotherapy instillations (with without previous si) improve rfs intermediate-risk patients.2a